RT Journal Article
SR Electronic
T1 Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5679
OP 5685
VO 35
IS 10
A1 MARK THALGOTT
A1 BRIGITTE RACK
A1 THOMAS HORN
A1 MATTHIAS M. HECK
A1 MATTHIAS EIBER
A1 HUBERT KÜBLER
A1 MARGITTA RETZ
A1 JÜRGEN E. GSCHWEND
A1 ULRICH ANDERGASSEN
A1 ROMAN NAWROTH
YR 2015
UL http://ar.iiarjournals.org/content/35/10/5679.abstract
AB Aim: Circulating tumour cells (CTCs) may be prognostic for biochemical recurrence-free survival (bRFS) in patients with locally advanced high-risk prostate cancer (LAPC) undergoing neoadjuvant chemohormonal therapy (NCHT) and radical prostatectomy (RP). Patients and Methods: CTCs were detected before and after NCHT, after RP and at follow-up using the CellSearch™-System for 59 blood samples (20 ml) from patients with LAPC (n=15) and, additionally, for 15 control samples. Results: The median 5-year progression risk was 90%. CTCs (≥1/20 ml) were detected in 53.3% of patients, with a detection rate of 18.6% in sample-adjusted analysis. CTCs were detected at baseline in 20% of patients with LAPC and 6.7% of controls (p=0.6). CTC findings displayed no association with clinicopathological characteristics. The median bRFS of CTC-negative vs. CTC-positive patients was 43.7 (95% confidence interval not reached) vs. 29.2 months (95% confidence interval=26.8-60.6 months), without statistical significance (p=0.76). Conclusion: During NCHT and RP, longitudinal CTC presence seems to some extent stochastic, although patients with persistant CTCs post-RP developed biochemical recurrence. No significant association with clinicopathological characteristics or bRFS was observed in patients with LAPC, despite a trend for reduced bRFS in patients with detectable CTCs.